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Recent studies have indicated that non-coding RNAs transcribed from enhancer regions are impor-
tant regulators of enhancer function and gene expression. In this report, we have characterised the
expression of six enhancer RNAs (eRNAs) induced in human monocytic THP1 cells following activa-
tion of the innate immune response by lipopolysaccharide (LPS). Speciﬁcally, we have demonstrated
that LPS-induced expression of individual eRNAs is mediated through divergent intracellular signal-
ling pathways that includes NF-jB and the mitogen activated protein kinases, extracellular regu-
lated kinase-1/2 and p38.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical
Societies. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).1. Introduction
Cells of the innate immune response, including circulating
monocytes, prevent infection through the rapid removal of invad-
ing pathogens [1]. Monocytes are able to detect micro-organisms
by a variety of mechanisms including the use of membrane associ-
ated pattern recognition receptors (PRR) that bind to conserved
components upon the pathogens. The best described is the Toll-like
receptor (TLR) family and in particular TLR4, which is activated by
lipopolysaccharide (LPS), a component of gram-negative bacteria
cell walls. TLR4 activation triggers intracellular signalling cascades,
most notably those that lead to activation of the transcription fac-
tor, nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-jB). In addition, LPS stimulation has been shown to stimulate
multiple mitogen activated protein kinase (MAPK) signalling path-
ways including extracellular signal-regulated kinases (ERK1/2), c-
Jun N-terminal kinases (JNK1/2) and p38 MAPK [2]. This ultimately
results in the activation of additional transcription factors involved
in the antimicrobial response including activator protein (AP-1)
and cAMP-responsive-element-binding protein 1 (CREB1) [3].
One of the mechanisms by which the expression of individual
genes can be potentially regulated by transcription factors isthrough interaction with enhancers, regulatory regions of the gen-
ome distally located from protein coding genes [4]. This is thought
to result in the looping of the chromatin structure which brings the
enhancer region into close proximity with the promoters of regu-
lated genes [5,6]. Interestingly, recent studies have indicated that
the action of enhancers is dependent upon the transcription of
non-coding RNAs, entitled enhancer RNAs (eRNAs) [7]. These are
involved both in the establishment of enhancer sites and in the
subsequent looping and regulation of gene expression in cis [8–13].
In previous reports, ourselves [13] and other investigators [14]
have identiﬁedwidespread induction of eRNAs following activation
of the innate immune response. In this report,wehave characterised
the expression of a range of eRNAs that are induced in response to
LPS stimulation ofmonocytic THP-1 cells. Since little is knownabout
the signalling pathways that regulate the production of these
immune-related eRNAs, we have examined the role of NF-jB and
the MAPK intracellular pathways and shown that the expression of
eRNAs is regulated by multiple divergent mechanisms.
2. Materials and methods
2.1. Culture of human monocytic THP-1 cells
Monocytic THP-1 cells were cultured in RPMI 1640, supple-
mented with 10% (v/v) FBS, L-glutamine (2 mM), 1% (v/v) Pen-Strep
J.A. Heward et al. / FEBS Letters 589 (2015) 396–406 397and0.1% (v/v)b-mercaptoethanol (InvitrogenGibco) and cultured in
a 37 C, 5% (v/v) CO2 humidiﬁed incubator.
2.2. Stimulation and drug treatment of monocytic THP-1 cells
Monocytic THP-1 cells were seeded at 5  105 cells/well in
500 ll in 24 well plates. Cells were treated with media or 1 lg/
ml LPS (Escherichia coli 055:B5, Sigma Aldrich) for 0–24 h (n = 3/
group/time-point). For the TLR agonists experiment, cells were
treated with PAM3CSK4 (100 ng/ml), HKLM (108 cells/ml), poly(I:C)
(10 mg/ml), poly(I:C) LMW (10 mg/ml), Flagellin (100 ng/ml), FSL-
1 (100 ng/ml), Imiquimod (5 lg/ml), ssRNA40 (1 lg/ml) and
ODN2006 (2 lM) (all from InvivoGen). In addition, THP-1 cells
were also treated with buffer (control), LPS and IL-1b (10 ng/ml,
recombinant, E. coli, Sigma Aldrich). For drug treatments, cells were
incubated with DMSO (vehicle control) or 0.1–10 lM of TPCA-1
(IjB kinase-2 inhibitor, Sigma–Aldrich), PD0325901 (MEK inhibi-
tor, Tocris) and SCIO 469 (p38 inhibitor, Tocris) for 30 min, prior
to stimulation with LPS for 4 h.
2.3. RNA isolation and cDNA synthesis
Total RNA was extracted using the Qiagen RNeasy kit which
included an on-column DNase treatment. cDNA was synthesised
using the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems).
2.4. qRT-PCR quantiﬁcation of RNA expression
Expression of eRNAs, mRNAs and 18S RNA was determined by
qRT-PCR using the SYBR Green PCR mix (Applied Biosystems).
The separate well, 2(DDCt) method was used to determine rela-
tive-quantities of individual mRNAs and eRNAs which were nor-
malised to 18S RNA. Primers used are listed in Table 1.Table 1
Sequences of qRT-PCR primers and siRNAs.
Primers
qRT-PCR Forward primer
18S rRNA AAACGGCTACCACATCCAAG
IL6 ACTCACCTCTTCAGAACGAAT
SOD2 GCTCCGGTTTTGGGGTATCTG
p65 ATGTGGAGATCATTGAGCAG
MALAT1 CTTAAGCGCAGCGCCATTTT
MT-CYB TAGACAGTCCCACCCTCACA
MARCKS-eRNA CACCACCCAGAAGATGCTGA
ACSL1-eRNA ACCATCGCAAGCTGCCCAGG
AZIN1-eRNA GGGGTGTGTGGGTGATTAGG
TNFSF8-eRNA TCCTCCTCCTAAGTGTGGGT
SLC30A4-eRNA GTGATGTGACAGCGTACGGC
SOCS3-eRNA TGTGGGTGGAGACACCTGGG
ChIP Forward primer
SOD2 CCTGGTGTCAGATGTTGCCT
IL6 AAAGGAGTCACACACTCCACC
SLC30A4-eRNA TTTTGCGCCTTCCTGGTGTT
SOCS3-eRNA TCTGCAAACCTGGTTGGTCC
AZIN1-eRNA AGGTTAGCTGGTGTTTTCTTA
TNFSF8-eRNA GATGACACTTGAGTCCGCCA
MARCKS-eRNA CACCACCCAGAAGATGCTGA
ACSL1-eRNA GGGAAAGGGACATACCTGGC
siRNAs
siRNA name Sequence
Scrambled UGGUUUACAUGUCGACUAA
Anti-p65 1 GGAUUGAGGAGAAACGUAA
Anti-p65 2 CCCACGAGCUUGUAGGAAA2.5. Nuclear-cytoplasm RNA fractionation
Monocytic THP-1 cells were stimulated with LPS for 2 h or 6 h.
The cells were centrifuged and then split into two equal fractions.
Total RNA was extracted from one fraction using the normal Qia-
gen RNeasy protocol whilst the other fraction was treated with
RLN buffer on ice for 5 min, in order to lyse the plasma membrane
whilst leaving the nuclei intact. The nuclei were then isolated by
centrifugation at 300g in a pre-chilled centrifuge. RNA was
extracted from the nuclear and cytoplasm fractions using the nor-
mal Qiagen RNeasy protocol. In order to quantify gene expression
within the different fractions by qRT-PCR, the 18S values from
the total RNA fraction were used to normalise the data.
2.6. Transfection of monocytic THP-1 cells with anti-p65 siRNAs
Monocytic THP-1 cells were seeded at 2.5  105 cells/well in 24
well plates, in 100 ll of complete growth medium. Transfection
mixes were prepared using 95 ll of serum-free growth medium,
5 ll of HiPerFect (QIAGEN) plus siRNAs to give a ﬁnal concentration
of 30 nM. Cells were subsequently incubated for 6 h, diluted with
400 ll of complete growth medium, incubated for a further 42 h
and then stimulated with LPS for 2 h. siRNA sequences are listed in
Table 1.
2.7. Detection of p65 and MAP kinases using Western blotting
Monocytic THP-1 cells were seeded at 1.5  106 cell/well in 12
well plates and transfected with siRNAs (see above). Cells were
lysed in buffer containing 50 mM Tris–HCl, 150 mM NaCl, 1%
(v:v) Nonidet P40, 1 mM sodium vanadate, 1 mM sodium moly-
bate, 10 mM sodium ﬂuoride, 40 lg/ml PMSF, 0.7 lg/ml pepstatin
A, 10 lg/ml aprotinin, 10 lg/ml leupeptin and 10 lg/ml soybean
trypsin inhibitor. Lysed samples were subsequently diluted in sam-Reverse primer
CCTCCAATGGATCCTCGTTA
TG CCATCTTTGGAAGGTTCAGGTTG
GCGTTGATGTGAGGTTCCAG
C CCTGGTCCTGTGTAGCCATT
GGCCAGCCTATAAGGACAGC
CGTGCAAGAATAGGAGGTGGA
A GGCCATGCGTTATGTTTCTTGA
CCTGGGTCCGCCCGTAGACAT
CCCTGGAGTACCAAGCTTCC
CCACACAGGAGGGATGCAAG
A ACTTCCTTTGGGTTTGGGGCAGA
C CTGGCTTCTCTCAGCCGGGG
Reverse primer
GGGAAAAGGCCCCGTGATTT
CCTGTGAGCGGCTGTTGTA
GGACTCTTGCTCTCACCAGC
GATCCCTGGCGTGCCTATTC
TTGG GGCAACCCTACCACTTTAGGT
AGCAGGGGAACGGCAATTAT
A GGCCATGCGTTATGTTTCTTGA
CCTCTCAGTCACAAGACGGC
Source
Dharmacon
Dharmacon
Dharmacon
Fig. 1. Example of immune-regulated eRNA in monocytic THP-1 cells. eRNAs genes are demarcated by high H3K4me1 and expressed co-ordinately with neighbouring genes.
ACSL1 is an example of a protein coding gene with an upstream eRNA gene, both of which are upregulated upon LPS stimulation. RNA-seq data from control (red) and LPS
stimulated (blue) monocytes are displayed in the top two tracks. The middle two panels display ChIP-seq data from human monocytes indicating the methylation status of
H3K4, with H3K4me1 (enhancer mark) displayed in orange and H3K4me3 (promoter mark) in green. The bottom panel displays transcription factor binding sites identiﬁed in
the ENCODE project [23], transcribed enhancers identiﬁed in the FANTOM project [16] and gene annotations for ACSL1 from RefSeq (blue) and ACSL1-eRNA (black; [13]).
Figure produced using the UCSC genome browser.
Table 2
Transcription factor binding sites, identiﬁed in the ENCODE project [23], and
transcribed enhancer regions identiﬁed by the FANTOM project that overlap with
eRNA gene bodies. Overlap with eRNA promoters (from +500 bp to 2 kb relative to
the transcription start site) is indicated in brackets.
Gene p65 JUN FOS JUND FANTOM enhancer
ACSL1 eRNA 5 (0) 2 (0) 7 (0) 4 (1) 3 (0)
MARCKS eRNA 5 (0) 1 (0) 4 (0) 4 (0) 7 (0)
AZIN1 eRNA 1 (0) 0 (0) 1 (0) 0 (0) 2 (0)
TNFSF8 eRNA 3 (1) 2 (0) 3 (1) 3 (0) 4 (1)
SLC30A4 eRNA 1 (0) 1 (0) 4 (1) 3 (0) 4 (0)
SOCS3 eRNA 3 (1) 0 (1) 1 (1) 1 (2) 1 (1)
IL6 0 (1) 2 (3) 1 (1) 2 (0) 0 (0)
SOD2 2 (1) 0 (1) 1 (2) 2 (3) 0 (0)
398 J.A. Heward et al. / FEBS Letters 589 (2015) 396–406ple buffer containing 5% b-mercaptoethanol, boiled and then sepa-
rated by electrophoresis on a 10% SDS–PAGE gel. Proteins were
transferred to a nitrocellulose membrane and probed with rabbit
anti-p65 (NF-jB p65, C-20, Santa Cruz), rabbit anti-pERK-1/2, p-
p38, ERK-1/2 and p38 (Phospho-MAPK Family Antibody and MAPK
Family Antibody Sampler kit, Cell Signaling) or rabbit anti-GAPDH
(D16H11, Cell Signaling Technology). The membranes were subse-
quently incubated with HRP-conjugated goat anti-rabbit secondary
antibody (DAKO) and bands visualised using an EZ-ECL chemilumi-
nescence detection kit (Geneﬂow, Staffordshire, UK) and Image-
Quant developer (GE healthcare, Buckingamshire, UK).2.8. Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed accord-
ing to the manufacturer’s guidelines (Active Motif; 53040). In brief,
3  107 THP1 cells were stimulated or not with LPS (1 lg/ml) for
60 min. Whole cells were cross-linked with a 1% formaldehyde
solution for 15 min at room temperature. Cells were sonicated
(Branson Soniﬁer 250) for 2 cycles (output: 1, duty cycles: 20%,
time: 30 s on 30 s off). DNA concentrations were quantiﬁed, and
10 lg of chromatin DNA was used for each ChIP reaction. ChIP
assays were performed with 4 lg of antibody (NFjB p65, C-20,
Santa Cruz) and incubated overnight at 4 C, precipitated with aga-
rose beads (supplied) and washed. Bead-bound DNA was reverse
cross-linked and puriﬁed with DNA Puriﬁcation columns (sup-
plied). Samples were then analysed by qPCR using the probes listed
in Table 1.
3. Results
3.1. eRNAs are differentially expressed following LPS stimulation
In a previous publication, we used RNA-seq to interrogate the
transcriptome of control and LPS stimulated human monocytes
and identiﬁed 76 multi-exonic, mono-directionally transcribed
eRNAs that were regulated by LPS plus 35 bi-directionally tran-
scribed eRNAs [13]. eRNAs were deﬁned as having a high
H3K4me1/H3K4me3 ratio in line with previous reports [15] and
annotated according to the nearest expressed protein coding gene
Fig. 2. Time course of LPS-induced mRNA and eRNA expression. Human monocytic THP-1 cells were exposed to either buffer or 1 lg/ml LPS for the indicated period of time
prior to quantiﬁcation of (a) IL6 and SOD2 mRNA and (b) SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA by qRT-PCR. Data is the
mean ± S.E.M. of 3 independent experiments.
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expression with neighbouring genes, the majority of which were
associated with the inﬂammatory response. An example of an
LPS-induced eRNA neighbouring and co-expressed with the gene
long-chain acyl-CoA synthetase (ACSL) 1, is shown in Fig. 1. ACSL1
esteriﬁes long chain fatty acids, a preliminary step in the biogene-
sis of lipid mediators including the pro-inﬂammatory prostaglan-
din E2. ACSL1-eRNA, 10 kb upstream of ACSL1, overlapped with
the binding sites of multiple transcription factors shown previ-
ously to regulate the inﬂammatory response, including sub-units
of NF-jB (RelA/p65) and AP-1 (c-fos, c-jun) [2]. In addition,
ACSL1-eRNA overlapped with enhancer regions recently classiﬁed
by the FANTOM project [16]. The overlap between transcriptionfactor binding sites and the enhancer regions characterised by
the FANTOM project was also observed with ﬁve other eRNAs;
SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA and
MARCKS-eRNA (Table 2).
3.2. eRNA expression rapidly peaks following LPS stimulation of THP-1
monocytic cells
To begin to characterise eRNA expression, we initially examined
the time course of LPS-induced expression of two key inﬂamma-
tory genes, SOD2 and IL6 [17–19] and the six immune-related
eRNAs, SLC30A4-eRNA, SOC3-eRNA, AZIN1-eRNA, TNFSF8-eRNA,
MARCKS-eRNA and ACSL1-eRNA. As expected, we observed a rapid
Fig. 3. Proﬁle of mRNA and eRNA expression is response to exposure to TLR agonists and IL-1b. Human monocytic THP-1 cells were exposed to buffer, a range of TLR agonists
or IL1b for 2 h. TLR agonists included the synthetic bacterial lipoprotein (Pam3CSK4 acting via TLR-1/2), a heat-killed preparation of the gram-positive bacterium Listeria
monocytogene (HKLM acting via TLR-2), synthetic mimics of double stranded RNA (polyIC and polyIC LMW acting via TLR-3), the bacterial ﬂagellin protein (acting via TLR-5),
a synthetic lipoprotein derived from Mycoplasma salivarium (FSL-1 acting via TLR-2/6), an imidazoquinoline amine analog to guanosine (Imiquimod acting via TLR-7), A GU-
rich single stranded RNA (ssRNA40 acting via TLR-8) and a CpG containing oligonucleotide (ODN2006 acting via TLR-9). Expression of (a) IL6 and SOD2 mRNA and (b)
SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA was quantiﬁed by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments.
Statistical signiﬁcance was determined using a one way ANOVA with a Dunnett’s post-test, where ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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expression throughout the 24 h period (Fig. 2a). All of the eRNAs
demonstrated rapid induction with expression peaking between
2 h and 6 h (Fig. 2b).
3.3. eRNA expression is induced by TLR4 and TLR6/2 receptor
activation
We next determined the proﬁle of expression following activa-
tion of other members of the TLR family (TLR1-9), as well as the
inﬂammatory cytokine IL-1b. Both the inﬂammatory markers and
the eRNAs displayed a similar expression proﬁle, with signiﬁcant
expression only seen in response to LPS (TLR4 agonist) and FSL-1,
which acts through the TLR6/2 heterodimer (Fig. 3). Although thisneeds to be investigated further, it is likely that the latter response
is mediated predominantly via TLR6, since the TLR2 agonist
(HKLM) had no signiﬁcant action (Fig. 3).
3.4. LPS-induced eRNA expression is predominantly restricted to the
nucleus
We next sought to determine whether the expression of LPS-
induced eRNAs was restricted to the nucleus, consistent with their
purported role as regulators of transcription [8,20,21]. To this end,
control and LPS stimulated monocytic THP-1 cells were subjected
to subcellular fractionation and RNA expression relative to whole
cells was examined by qRT-PCR. Successful subcellular fraction-
ation was conﬁrmed following the observation that the nuclear
Fig. 4. Subcellular distribution of mRNA and eRNA expression. Human monocytic THP-1 cells were stimulated with LPS for 2 h or 6 h prior to RNA extraction from either total
cells or the nuclear and cytoplasm fractions. qRT-PCR was then used to analyse the expression and distribution, relative to a total cell fraction, of (a) IL6 and SOD2mRNA and
(b) SLC30A4-eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments.
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Fig. 6. Pharmacological analysis of the signalling pathways that regulate LPS-induced e
control) or pharmacological inhibitors of IKK2 (TPCA-1), MEK (PD0325901) and p38 (SCI
eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA expression was quantiﬁed by qRT-P
was determined using a one way ANOVA with a Dunnett’s post-test, where ⁄P < 0.05, ⁄⁄
Fig. 5. Pharmacological analysis of the signalling pathways that regulate LPS-
induced SOD2 and IL6 mRNA expression. Human monocytic THP-1 cells were
treated with DMSO (vehicle control) or pharmacological inhibitors of IKK2 (TPCA-
1), MEK (PD0325901) and p38 (SCIO 469) for 30 min prior to LPS stimulation (4 h).
IL6 and SOD2 expression was quantiﬁed by qRT-PCR. Data is the mean ± S.E.M. of 3
independent experiments. Statistical signiﬁcance was determined using a one way
ANOVA with a Dunnett’s post-test, where ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
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adenocarcinoma transcript 1) [22] and mitochondrial mRNA MT-
CYB (mitochondrially encoded Cytochrome B) was restricted to
the nuclear and cytoplasmic fractions, respectively (data not
shown see Ref. [13]). As supported by the time course data
(Fig. 2a), IL6 expression was found to be equally distributed
between the cytoplasm and nucleus, implying on-going transcrip-
tion whilst SOD2 was predominant located in the cytoplasm
(Fig. 4a). In the case of the eRNAs, 4 (SCL30A4-eRNA, SOCS3-eRNA,
AZIN1-eRNA and TNFSF8-eRNA) demonstrated strong nuclear
enrichment whilst MARCKS-eRNA and ACSL1-eRNA were expressed
in both fractions (Fig. 4b).
3.5. LPS-induced eRNA expression is regulated by the NF-jB signalling
pathway
Following the activation of TLR4, a number of signalling path-
ways including those that act through IKK2 (upstream activator
of NF-jB) and members of the MAP kinase families are thought
to regulate inﬂammatory gene expression via activation of tran-
scription factors [2]. We therefore sought to determine whether
these signalling pathways might also regulate LPS-induced eRNA
expression through the use of pharmacological inhibitors.
The role of IKK2 upon the LPS-induced response at 4 h was ini-
tially examined using the pharmacological inhibitor, TPCA-1. As
expected, the LPS-induced SOD2 and IL6 expression was repressed
with IC50 values of 2.7 lM and 0.27 lM, respectively (Fig. 5). Inter-
estingly, all of the LPS-induced eRNAs were signiﬁcantly repressed
following inhibition of IKK2, with IC50 values ranging from
0.083 lM (TNFSF8-eRNA) to 3.24 lM (SOCS3-eRNA) (Fig. 6). It was
not possible to determine an IC50 value for ACSL1-eRNA, as only
the highest concentration of TPCA-1 inhibited its expression.
To provide additional evidence of a role for NF-jB in LPS-
induced eRNA expression we undertook studies using siRNA-med-
iated knockdown and chromatin immunoprecipitation (ChIP) in
combination with qRT-PCR. Using two siRNAs targeted to the p65RNA expression. Human monocytic THP-1 cells were treated with DMSO (vehicle
O 469) for 30 min prior to LPS stimulation (4 h). SLC30A4-eRNA, SOCS3-eRNA, AZIN1-
CR. Data is the mean ± S.E.M. of 3 independent experiments. Statistical signiﬁcance
P < 0.01 and ⁄⁄⁄P < 0.001.
Fig. 7. Effect of siRNA-mediated knockdown of p65 NF-jB upon LPS-induced mRNA and eRNA expression. Human monocytic THP-1 cells were transfected with either a non-
targeting negative control siRNA or 2 siRNAs targeting p65, for 6 h at 30 nM and then diluted to 10 nM for 42 h, before exposure to buffer or 1 lg/ml LPS for 2 h. The
expression of the following was subsequently examined; (a) p65 mRNA by qRT-PCR and p65 protein by Western blot, (b) SOD2 and IL6 mRNA by qRT-PCR and (c) SLC30A4-
eRNA, SOCS3-eRNA, AZIN1-eRNA, TNFSF8-eRNA, MARCKS-eRNA and ACSL1-eRNA by qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments. Statistical signiﬁcance
was determined using a one way ANOVA with a Dunnett’s post-test, where ⁄P < 0.05, ⁄⁄P < 0.01 and ⁄⁄⁄P < 0.001.
J.A. Heward et al. / FEBS Letters 589 (2015) 396–406 403subunit of NF-jB we showed a signiﬁcant decrease in the mRNA
expression and protein level of p65, whereas no knockdown was
observed following transfection with the negative control
(Fig. 7a). Knockdown of p65 by both siRNAs signiﬁcantly reduced
the LPS-induced mRNA levels of SOD2 and IL6 (Fig. 7b). Similarly,
the LPS-induced expression of all of the eRNAs was also impaired.
Thus, signiﬁcant decreases in LPS-induced expression of AZIN1-
eRNA, TNFSF8-eRNA, MARKS-eRNA and ACSL1-eRNA were observed
although the decreases in LPS-induced expression of SLC30A4-eRNA
and SOC3-eRNA did not reach signiﬁcance (Fig. 7c). Chromatin
immunoprecipitation (ChIP) using an antibody to the p65 RelA
DNA binding, was employed to measure NF-jB activation and
binding in the absence and presence of IKK2 inhibitor. Although
this only reached signiﬁcance in 50% of the genes examined, these
studies showed a general trend for increased NF-jB binding within
the predicted promoter regions of SOD2, SLC30A4-eRNA, AZIN-1-eRNA, SOCS3-eRNA, TNFSF8-eRNA and ACSL1-eRNA and that this
was reversed in the presence of the IKK2 inhibitor (Fig. 8). In con-
trast, we observed no NF-jB binding in the promoter region of IL6
orMARCKS-eRNA (Fig. 8). The reasons for the variability in the ChIP
studies is unclear although it could relate to a number of factors
including the difﬁculties in predicting the NF-jB binding region
(for qRT-PCR probe design) and the transient nature of NF-jB bind-
ing. Overall, this data suggested that the NF-jB signalling pathway
has a key role in regulating LPS-induced eRNA expression.
3.6. LPS-induced eRNA expression is regulated by the MAP kinase
signalling pathways
UsingWestern blotting, we were able to demonstrate activation
of the ERK-1/2 and p38 using phosphoantibodies to detect the acti-
vation forms of these MAP kinases (Fig. 9). Importantly, following
Fig. 8. Measurement of NF-jB binding at mRNA and eRNA promoters using chromatin immunoprecipitation. Human monocytic THP-1 cells were exposure to buffer or 1 lg/
ml LPS for 1 h in the presence or absence of 10 lM TPCA-1 prior to p65 NF-jB chromatin immunoprecipitation. Binding within the promoter regions of the speciﬁed mRNA
and eRNA were quantiﬁed using qRT-PCR. Data is the mean ± S.E.M. of 3 independent experiments. Statistical signiﬁcance was determined using a one way ANOVA with a
Dunnett’s post-test, where ⁄ P < 0.05 and ⁄⁄⁄P < 0.001 versus non-stimulated controls and $P < 0.05 and $$$P < 0.001 versus stimulated samples in the absence of TPCA-1.
404 J.A. Heward et al. / FEBS Letters 589 (2015) 396–406the observation that this phosphorylation/activation could be com-
pleted attenuated in the presence of the selective MEK-1/2
(PD0325901) and p38 (SCIO 469) inhibitors (Fig. 9), these com-
pounds were employed to examine the role of these pathways in
the regulation of eRNA expression. In addition to IL6, these studies
indicated that the expression of AZIN1-eRNA and TNFSF8-eRNA
were mediated via the ERK-1/2 pathways (Figs. 5 and 6). In the
case of p38 inhibitor, our investigations showed a role for this
pathway in the LPS-induced expression of SOD2, IL6, TNFSF8-eRNA
and ACSL1-eRNA (Figs. 5 and 6). Of relevance, we were unable to
demonstrate phosphorylation/activation of JNK-1/2 or an effect of
the JNK inhibitors SP600125 (at 10 lM) upon LPS-inducedexpression of SOD2, IL6 and eRNAs (data not shown). It therefore
appears that in addition to NF-jB, the expression of a number of
eRNAs are regulated via ERK-1/2 and p38.
3.7. Discussion and conclusions
Advances in sequencing technology have begun to reveal the
startling complexity of the human epigenome including the wide-
spread occurrence of enhancer regions, with approximately
400000 putative enhancers having been identiﬁed as part of the
ENCODE project [23]. Importantly, it is becoming apparent that
the action of these enhancers is dependent upon the production
Fig. 9. Inhibition of LPS-mediated ERK-1/2 and p38 phosphorylation. Humanmonocytic THP-1 cells were treated with DMSO (vehicle) or 10 lM of pharmacological inhibitors
of MEK (PD0325901) or p38 MAPK (SCIO 469) for 30 min prior to LPS stimulation (30 min). (a) The level of ERK-1/2 and p38 phosphorylation was assessed by Western blot
(representative experiment shown) and (b) the levels of phosphorylation were quantiﬁed using ImageJ software. Data is the mean ± S.E.M. of 3 independent experiments.
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identiﬁed 43000 bi-directionally transcribed eRNAs across a
diverse range of human tissues [16]. Interestingly, dynamic activa-
tion and repression of enhancers has been shown to occur upon
exposure of immune cells to inﬂammatory stimuli, suggesting that
enhancers have a key role in regulating inﬂammatory gene expres-
sion [13,14,24]. Furthermore, one of the key ﬁndings of the FAN-
TOM project was that immune cells such as monocytes, in
contrast to terminally differentiated cell types such as epithelial
cells, express high relative numbers of eRNAs [16].
However, despite the increasing evidence to suggest the impor-
tance of eRNAs in the immune response, little is known about the
signalling pathways that regulate their expression. To address this
question, we have characterised the mechanisms that regulate 6
eRNAs that are induced in response to LPS [13]. All of these eRNAs
overlapped with enhancer regions identiﬁed by the FANTOM pro-
ject [16] and contained numerous binding sites for inﬂammatory
transcription factors. In support of the observation that eRNAs reg-
ulate gene expression [8,14], we showed rapid induction of eRNA
expression that preceded or correlated with expression of other
inﬂammatory genes upon LPS exposure. Furthermore, distribution
studies showed that the majority were located in the nucleus and
that their actions might therefore be mediated in cis. Interestingly,
the expression of two of the examined eRNAs was not restricted to
the nucleus, suggesting that some eRNAs might act in the cyto-
plasm. Examination of the intracellular signalling pathways indi-
cate that the NF-jB signalling pathway has a central role in
regulating LPS-induced eRNA activation, consistent with the
reports that NF-jB is required for activation of enhancers in
inﬂammation [14,25]. However, the expression of individual
eRNAs were also dependent on ERK-1/2 and p38, implying that
transcription and potentially the activation of these enhancers
requires multiple transcription factors in addition to NF-jB.In moving forward it will be necessary to investigate the func-
tion of these immune related eRNAs and the mechanisms that reg-
ulate their expression. On a genome scale, our previous studies
have shown that eRNAs expression is correlated with the localised
expression of mRNAs. Interestingly, the expression of the nearest
mRNAs which includes SLC30A4 (2 fold), AZIN1 (2 fold), SOC3 (14
fold), TNFSF8 (3 fold), MARCKS (7 fold) and ACSL1 (8 fold), were all
shown to be induced following LPS exposure. This correlation
implies that these eRNAs indeed function to regulate localised gene
expression although this would need to be conﬁrmed by eRNA
knockdown. Possibly as a result of their nuclear localisation and
rapid induction, these eRNAs knockdown studies have proven
problematic. However, this situation could be transformed by the
recent developments in the area of CRISPRi, which permits inhibi-
tion of eRNA transcription rather than the traditional post-tran-
scription approaches involving siRNAs and antisense [26].
Clearly, the other issue is the exact mechanism by which eRNA
expression is regulated within the enhancer regions. In addition
to NF-jB, this report indicates that transcription factors down-
stream of ERK-1/2 and p38 such as AP-1 might be also involved
in eRNA transcription. As with our studies on p65 (NF-kB), this
question can be addressed using ChIP to assess AP-1 binding at
eRNA sites and examining the effect of AP-1 knockdown upon
eRNA and mRNA expression.
In conclusion, we have characterised the mechanism that regu-
late the expression of multiple immune-regulated eRNAs and
shown that like inﬂammatory gene expression, this occurs through
divergent signalling pathways.
Acknowledgement
Mark A. Lindsay and Benoit Roux are supported by the BBSRC
(BB/K006223/1).
406 J.A. Heward et al. / FEBS Letters 589 (2015) 396–406References
[1] Medzhitov, R. (2008) Origin and physiological roles of inﬂammation. Nature
454, 428–435.
[2] Newton, K. and Dixit, V.M. (2012) Signaling in innate immunity and
inﬂammation. Cold Spring Harb. Perspect. Biol. 4, a006049.
[3] O’Neill, L.A.J., Golenbock, D. and Bowie, A.G. (2013) The history of Toll-like
receptors – redeﬁning innate immunity. Nat. Rev. Immunol. 13, 453–460.
[4] Stender, J.D. and Glass, C.K. (2013) Epigenomic control of the innate immune
response. Curr. Opin. Pharmacol. 13, 582–587.
[5] Blackwood, E.M. and Kadonaga, J.T. (1998) Going the distance: a current view
of enhancer action. Science 281, 60–63.
[6] Pennacchio, L.A., Bickmore, W., Dean, A., Nobrega, M.A. and Bejerano, G. (2013)
Enhancers: ﬁve essential questions. Nat. Rev. Genet. 14, 288–295.
[7] Natoli, G. and Andrau, J.-C. (2012) Noncoding transcription at enhancers:
general principles and functional models. Ann. Rev. Genet. 46, 1–19.
[8] Lam, M.T.Y., Li, W., Rosenfeld, M.G. and Glass, C.K. (2014) Enhancer RNAs and
regulated transcriptional programs. Trends Biochem. Sci. 39, 170–182.
[9] Melo, C.A. et al. (2013) ERNAs are required for p53-dependent enhancer
activity and gene transcription. Mol. Cell 49, 524–535.
[10] Li, W. et al. (2013) Functional roles of enhancer RNAs for oestrogen-dependent
transcriptional activation. Nature 498, 516–520.
[11] Lam, M.T.Y. et al. (2013) Rev-Erbs repress macrophage gene expression by
inhibiting enhancer-directed transcription. Nature 498, 511–515.
[12] Mousavi, K. et al. (2013) ERNAs promote transcription by establishing
chromatin accessibility at deﬁned genomic loci. Mol. Cell 51, 606–617.
[13] IIott, N.E. et al. (2014) Long non-coding RNAs and enhancer RNAs regulate the
lipopolysaccharide-induced inﬂammatory response in humanmonocytes. Nat.
Commun. 5. 3979.[14] Kaikkonen, M.U. et al. (2013) Remodeling of the enhancer landscape during
macrophage activation is coupled to enhancer transcription. Mol. Cell 51,
310–325.
[15] Heintzman, N.D. et al. (2007) Distinct and predictive chromatin signatures of
transcriptional promoters and enhancers in the human genome. Nat. Genet.
39, 311–318.
[16] Andersson, R. et al. (2014) An atlas of active enhancers across human cell
types and tissues. Nature 507, 455–461.
[17] Kishimoto, T. (2010) IL-6: from its discovery to clinical applications. Int.
Immunol. 22, 347–352.
[18] Tian, L. et al. (1998) Induction of Mn SOD in human monocytes without
inﬂammatory cytokine production by a mutant endotoxin. Am. J. Physiol. 275,
C740–7.
[19] Case, A.J. et al. (2011) Elevated mitochondrial superoxide disrupts normal T
cell development, impairing adaptive immune responses to an inﬂuenza
challenge. Free Radic. Biol. Med. 50, 448–458.
[20] Djebali, S. et al. (2012) Landscape of transcription in human cells. Nature 489,
101–108.
[21] Heward, J.A. and Lindsay, M.A. (2014) Long non-coding RNAs in the regulation
of the immune response. Trends Immunol. 35, 408–419.
[22] Tripathi, V. et al. (2010) The nuclear-retained noncoding RNA MALAT1
regulates alternative splicing by modulating SR splicing factor
phosphorylation. Mol. Cell 39, 925–938.
[23] Dunham, I. et al. (2012) An integrated encyclopedia of DNA elements in the
human genome. Nature 489, 57–74.
[24] Ostuni, R. et al. (2013) Latent enhancers activated by stimulation in
differentiated cells. Cell 152, 157–171.
[25] Teferedegne, B., Green, M.R., Guo, Z. and Boss, J.M. (2006) Mechanism of action
of a distal NF-kappaB-dependent enhancer. Mol. Cell. Biol. 26, 5759–5770.
[26] Gilbert, L.A. et al. (2014) Genome-Scale CRISPR-mediated control of gene
repression and activation. 159, 647–661.
